New antibody combo tackles tough cancers in early trial

NCT ID NCT07166601

Recruiting now Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Oct 01, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This early-stage study tests a new drug called M0324 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells and boost the immune system. Researchers will test M0324 alone, with another immunotherapy (pembrolizumab), or with chemotherapy to find safe doses and look for early signs of effectiveness. About 77 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Icahn School of Medicine at Mount Sinai
NOT_YET_RECRUITING

New York, New York, 10029, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78249, United States
National Cancer Center Hospital
RECRUITING

Chūōku, Japan
Princess Margaret Cancer Centre
RECRUITING

Toronto, Canada
Yale University School of Medicine
RECRUITING

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR